November 14, 2019

Sema4 Appoints Biotech Leader Joel Sendek as Chief Financial Officer

 

Stamford, CT — November 14, 2019 — Sema4, a patient-centered health intelligence company, today announced the appointment of Joel Sendek as Chief Financial Officer. Mr. Sendek has more than 25 years of financial leadership experience in the pharmaceutical and biotechnology sector, including overseeing the successful initial public offerings at his last two companies.

“As Sema4’s growth continues to accelerate, building relationships with patients and providers to provide more actionable clinical guidance, Joel’s experience with fundraising and running the finances of publicly traded companies will be invaluable,” said Eric Schadt, Ph.D., Founder and Chief Executive Officer of Sema4. “I am delighted to welcome him to our rapidly growing team and look forward to the significant contributions he will make for us and for the patients, physicians, and healthcare systems we’re helping every day.”

Mr. Sendek commented: “Sema4 has already made tremendous strides in health intelligence and genomic testing, and I believe the company is now poised for even more transformative growth. I am excited to join this vibrant company as it brings better care to the fields of oncology, women’s health, and beyond.”

Previously, Mr. Sendek served as Chief Financial Officer at Spero Therapeutics for more than two years and held the same position at Forward Pharma the three years before that. He spent more than 15 years as a senior equity research analyst covering the biotech field and leading healthcare equity research at Stifel Financial Corp. and Lazard. Prior to his career in equity research, Mr. Sendek worked as a Senior Director of Corporate Development at Progenics Pharmaceuticals and as an investment banking analyst at Goldman Sachs. He earned his B.A. in biochemistry at Rice University.

 

About Sema4

Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedInFacebook and YouTube.


Media Contact

Nicole Litchfield
415.370.5804
nicole@bioscribe.com